|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||NCI-H69/CPR|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: NCI-H69/CPR (ECACC 96042328)|
|Keywords:||Human small cell lung cancer, drug-resistant|
|Cell Line Description:||NCI-H69/CPR is a drug resistant subline of NCI-H69 (ECACC catalogue no. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.|
|Tissue of Origin:||Lung|
|Growth Mode:||Aggregates in suspension|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37ºC; resuscitate in drug-free medium until first passage.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 0.4µg/ml cisplatin + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr P Twentyman, Dr. K. Wright, UKCCR, PO Box 123, Lincolns Inn Fields, London WC2A 3PX|
|References:||Br J Cancer 1992;65:684, Cancer Res 1992;52:5674|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.